Sarepta Therapeutics, Inc. $SRPT Shares Purchased by Virtus Advisers LLC

Virtus Advisers LLC lifted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 114.9% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 58,244 shares of the biotechnology company’s stock after purchasing an additional 31,146 shares during the period. Virtus Advisers LLC owned about 0.05% of Sarepta Therapeutics worth $1,061,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Meeder Asset Management Inc. bought a new stake in Sarepta Therapeutics during the second quarter valued at approximately $27,000. Pinnacle Wealth Planning Services Inc. increased its holdings in Sarepta Therapeutics by 50.6% during the third quarter. Pinnacle Wealth Planning Services Inc. now owns 1,780 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 598 shares during the last quarter. Nykredit A S purchased a new stake in Sarepta Therapeutics during the second quarter valued at approximately $43,000. Ancora Advisors LLC bought a new position in Sarepta Therapeutics in the second quarter worth approximately $45,000. Finally, Allworth Financial LP bought a new position in Sarepta Therapeutics in the second quarter worth approximately $58,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT traded up $0.06 on Friday, reaching $16.07. 1,324,817 shares of the stock were exchanged, compared to its average volume of 2,306,892. Sarepta Therapeutics, Inc. has a one year low of $14.68 and a one year high of $24.68. The firm has a market capitalization of $1.72 billion, a PE ratio of -11.73, a PEG ratio of 0.38 and a beta of 0.45. The company’s 50-day simple moving average is $18.59 and its two-hundred day simple moving average is $18.51. The company has a current ratio of 3.46, a quick ratio of 2.13 and a debt-to-equity ratio of 0.46.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.05. The business had revenue of $381.35 million for the quarter, compared to the consensus estimate of $352.20 million. Sarepta Therapeutics had a negative net margin of 5.86% and a negative return on equity of 0.20%. The company’s revenue for the quarter was down 4.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.13) earnings per share. Analysts expect that Sarepta Therapeutics, Inc. will post 3.27 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on SRPT shares. Zacks Research cut shares of Sarepta Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, October 5th. HC Wainwright restated a “sell” rating and issued a $5.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, October 5th. Wall Street Zen cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Needham & Company LLC reaffirmed an “underperform” rating on shares of Sarepta Therapeutics in a report on Monday, September 28th. Finally, Benchmark reiterated a “sell” rating on shares of Sarepta Therapeutics in a research report on Wednesday, September 9th. Six analysts have rated the stock with a Buy rating, six have issued a Hold rating and six have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Sarepta Therapeutics currently has a consensus rating of “Hold” and an average price target of $23.67.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics is a biotechnology company focused on developing genetic medicines for rare diseases, with an emphasis on Duchenne muscular dystrophy (DMD). Its research includes RNA-based treatments designed to affect how genetic instructions are processed, as well as gene therapy approaches. The company’s DMD medicines include exon-skipping therapies such as eteplirsen (Exondys 51), golodirsen (Vyondys 53) and casimersen (Amondys 45). Each is intended for patients with a specific genetic mutation and works by helping cells produce a shortened form of dystrophin, a protein affected by DMD.